Ian McCubbin, CBE
Chair, Cell and Gene Therapy Catapult, & Chair, RoslinCT
Ian is the Chair of RoslinCT, a cell therapy contract development and manufacturing organization based in Edinburgh and Boston. RoslinCT has its lineage to Dolly the sheep, Edinburgh Univ. and the Roslin Institute. This deep experience and know how has positioned the company at the leading edge of this transformational medical treatment modality.
He is the Chair of the UK Cell and Gene Therapy Catapult, which was set up more than a decade ago to support the advanced therapy endeavor and to put the UK front and centre of this novel wave of medical advancement in a very competitive global environment.
Ian is a Non Executive director of the Bio-Industry Association.
He was a member of the UK Government Vaccines Task Force between Jan 2020-July 21 working with Kate Bingham and her team to accelerate availability of vaccines during the COVID pandemic. His role was to lead the manufacturing stream to help developer’s ensure that the UK resources and ecosystem could be deployed to aid and speed development , scale up and manufacturing of vaccines both for the UK and for global use.
He retired from his role (SVP Global Supply ) with GSK in April 2017. He was responsible for 17 factories and 7,000 employees globally which supplied the New Product pipeline and the majority of GSK’s pharmaceutical sales.
He was a Director of ViiV Healthcare a joint venture between GSK, Pfizer and Shionogi , a specialist HIV focused company.
Ian co-chaired the Advanced Therapy Manufacturing Task Force originally with George Freeman, Minister for Life Sciences and the group published its Action Plan to ‘anchor’ commercial scale manufacturing in the UK. The Action Plan has subsequently been adopted in full as part of the Life Sciences Industrial Strategy.
Ian Qualified as pharmacist and worked in hospital and retail early in his career.